Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Slides:



Advertisements
Similar presentations
Skip Counting Counting by 2, 5, and 10.
Advertisements

Take Five to Understand! 1. Eat Healthier Eating fewer calories and cutting down on saturated fat and carbohydrates can help lower weight, blood glucose.
The ‘game’ is played by 12 players and 2 Accountants. The accountants and the first player can volunteer. Other players Are chosen as the game progresses.
Presented by Slyter Nutrition Consulting Services.
Major recommendation for statin therapy for ASCVD prevention
Vanguard Phase Results for the Blood Pressure Component
Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’
Skip Counting Counting by 2, 5, and 10.
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Skip Counting Counting by 2, 5, and 10.
Comparison of the LL95%CI rule to PE rules with similar behaviour, when the true HR is different from the design HR: %acceptance of maximal relative benefit,
Martin Bødtker Mortensen, and Erling Falk JACC 2018;71:85-94
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.
Sudden Unexpected Death in North Carolina (SUDDEN) Gender and Ethnicity by Age—the majority of the cohort is over age 55 years, especially black men but.
OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.
Longitudinal MWF in different brain regions for the vaginal delivery (blue) and cesarean delivery (green) groups in cohort 3. Longitudinal MWF in different.
Description of studies for pooled analyses
Patient reactions to a web-based cardiovascular risk calculator in type 2 diabetes: a qualitative study in primary care by Tom Nolan, Charlotte Dack, Kingshuk.
Frequency counts of exercise intensities routinely prescribed in programmes (n=194) grouped by method/scale. Frequency counts of exercise intensities routinely.
Level of risk factor control in the overall sample and by gender
Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.
Masashi Maeda et al. Heart Asia 2013;5:7-14
Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.
Histograms of pressure wire FFR values for FFRMC and FFRPW
Patients’ preferences do not always match maximisation of lifespan.
Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.
Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.
Excluded and adjudicated male and female referrals—living and deceased participants were referred to the Sudden Unexpected Death in North Carolina (SUDDEN)
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.
(A and B) Changes in the apnoea hypopnoea index (AHI) and 3% oxygen desaturation index (ODI) from baseline to treatment titration and 3 months of therapy:
Comparison of CMR and echocardiography in aortic regurgitation.
Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.
The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.
Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.
Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.
The volume per centre plotted against clinical outcomes which included Hospital Anxiety and Depression Scale (HADS) score, exercise 150 min, smoking, body.
Slope of FEV1 by age at enzyme replacement therapy (ERT) initiation FEV1 z-score slope (y-axis) by age categorised in three groups (red, ERT initiation 
Distribution of relative percentage change ((post-AVR−pre-AVR)/pre-AVR) in the patients’ absolute pVO2 values between pre-AVR and post-AVR after 9 months.
Receiver operating curves (ROC) of simple age and gender adjusted risk factor models for predicting 10-year risk of cardiovascular disease comparing the.
Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.
Change in 6 min walk distance from baseline to each follow-up time for subjects randomised to CABG and to medical therapy alone. The median change and.
Cost of healthcare and sick leave before and after heart valve surgery (€). Cost of healthcare and sick leave before and after heart valve surgery (€).
Actual age-adjusted rates for men aged 45–74 years related to systolic blood pressure (based on age-specific rates in Framingham study). Actual age-adjusted.
Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),
ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.
Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.
Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.
Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.
Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)
Cost-effectiveness plane for all PARTNER-B vs all ADVANCE and all PARTNER vs ADVANCE high risk comparisons with ICERs from five studies; dashed line represents.
Dimensions indexed to body surface area (AGA, appropriate birth weight for gestational age; SGA, small for gestational age; LVED, left ventricular end-diastolic;
Knowledge gaps in key risk factor numbers
Determinants of moderate Cardiovascular Health Index Score (CHIS) (achieving three or more risk factor targets). Determinants of moderate Cardiovascular.
Unadjusted event-free survival (days alive and out-of-hospital) of participants with and without MCI in (A) overall cohort, (B) standard management cohort.
Difference in cumulative revision of knee constructs compared with a contemporary benchmark at 7 years in men aged between 55 years and 75 years, using.
Calculating the overall accuracy in different samples using the V-plot
Heat map of microRNA microarray expression from the four groups of patients. Heat map of microRNA microarray expression from the four groups of patients.
Alcohol, Other Drugs, and Health: Current Evidence May–June 2019
Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.
Prevalence of regular non-steroidal anti-inflammatory drug (NSAID) use by age and race/ethnicity. Prevalence of regular non-steroidal anti-inflammatory.
HR for mortality in ischemic heart disease.
HR for myocardial infarction.
The distribution of systolic blood pressure (SBP) in male (blue) and female (red) athletes with mean values (SD) presented for each sex (panel A). The.
Relationship between 6-month all-cause mortality and the three types of heart failure adjusted for age ≥75 years, peripheral edema at admission, systolic.
The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.
Forest plot showing survival c-statistics for selected models, applied to the testing cohort. Forest plot showing survival c-statistics for selected models,
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Receiver operating characteristic curve showing results for two selected models, applied to the testing cohort. Receiver operating characteristic curve.
Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.
Presentation transcript:

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure and national average cholesterol. Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure and national average cholesterol. Each small square indicates one representative individual taking a lifetime of preventative therapy. For the individuals whose lifespans are longer with medication, a bar is drawn whose height represents their individual lifespan gain from medication: white columns represent individuals who gain no extra lifespan, yellow columns represent individuals who gain lifespan less than the group mean gain, blue columns represent individuals who gain an amount of lifespan similar to the group mean gain and green columns represent individuals whose gain is more than the group mean gain. The graph makes it clear that although only a minority of the cohort (7%) gain any lifespan from a lifetime of preventative therapy; nevertheless, this relatively small group gain is much more (99 months) than the group mean gain (7 months). Judith A Finegold et al. Open Heart 2016;3:e000343 ©2016 by British Cardiovascular Society